Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00864500 · ClinicalTrials.gov registry record · Phase 1

Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects

A Phase 1 study of Healthy, sponsored by Actavis.

Completed
Registry status
Phase 1
Development phase
224
Enrollment target
1
Study location

NCT00864500 is a Phase 1 study of Healthy that has completed, run by Actavis. The registered enrollment target is 224 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00864500, a Phase 1 study of Healthy, has completed, sponsored by Actavis.

COMPLETED
Registry status
Phase 1
Development phase
224 participants
Enrollment target
1
Study location

Study Summary

To compare the relative vasoconstrictive effects of two topical clobetasol propionate 0.05% lotions in asymptomatic subjects.

Conditions Studied

Interventions

  • DRUG Clobetasol Propionate 0.05% lotion, single exposure
  • DRUG Clobex TM 0.05% Lotion, single exposure

Study Locations (1)

Texas

  • Novum Pharmaceutical Research Services - Houston

Trial Details

FieldValue
Enrollment Target 224 participants
Start Date 2005-11
Est. Completion 2006-02
Phase Phase 1

Sponsor

Actavis

79 total trials

What the Registry Record Tells You About NCT00864500

The ClinicalTrials.gov registry entry for NCT00864500 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (65% lower). The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Clobetasol Propionate 0.05% lotion, single exposure is the first listed.

NCT00864500 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00864500 about?

NCT00864500 is a clinical study titled "Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects". To compare the relative vasoconstrictive effects of two topical clobetasol propionate 0.05% lotions in asymptomatic subjects.

What is the current status of trial NCT00864500?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 224 participants. The study started on 2005-11. Estimated completion is 2006-02.

What conditions does trial NCT00864500 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00864500?

The interventions under investigation include: Clobetasol Propionate 0.05% lotion, single exposure (DRUG), Clobex TM 0.05% Lotion, single exposure (DRUG).

Who is sponsoring clinical trial NCT00864500?

This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00864500 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.